The tumor suppressor CYLD regulates entry into mitosis

Area of Science:

• Oncology
• Cell Biology
• Molecular Biology

Background:

• Mutations in the cylindromatosis (CYLD) gene are linked to benign cylindroma tumors.
• CYLD encodes a deubiquitinating enzyme inhibiting the NF-kappaB pathway, impacting apoptosis resistance.
• The precise tumor-suppressing mechanisms of CYLD beyond apoptosis regulation remain unclear.

Purpose of the Study:

• To investigate the role of CYLD in cell cycle regulation, specifically mitotic entry.
• To explore potential novel functions of CYLD in tumorigenesis.
• To understand the implications of CYLD's functions for the benign nature of cylindromas.

Main Methods:

• Localization studies of CYLD protein during the cell cycle.
• Analysis of CYLD protein levels during mitosis.
• Identification of interacting proteins, such as Plk1, using loss-of-function and overexpression assays.

Main Results:

• CYLD is essential for timely entry into mitosis and localizes to microtubules and the midbody.
• CYLD protein levels decrease upon exiting mitosis.
• Physical interaction and similar phenotypic effects were observed between CYLD and Plk1, suggesting Plk1 as a target.

Conclusions:

• CYLD plays a critical role in regulating mitotic entry, in addition to its known function in apoptosis regulation.
• CYLD exhibits dual functions: tumor suppression via apoptosis regulation and potential tumor promotion by enhancing mitotic entry.
• This dual role may explain the benign characteristics of cylindroma lesions.